‘Roche could’ve earned over 100 times what it cost for rare disease drug’

Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its development costs. Roche disputes this, citing expenses from unsuccessful projects and ongoing research. While the drug remains unaffordable for many in India, Roche offers access programs and free treatment to some patients.Original Article

Related posts

Morning news wrap: CDS confirms jet losses; Tej Pratap’s plea to Lalu; PSG win Champions League; & more

Watch: Guwahati submerged as heavy rain causes severe waterlogging

All 7 NCP MLAs in Nagaland merge with NDPP, give CM Rio absolute majority in assembly